Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
NewsHigher levels of an Epstein-Barr virus antibody may help slow disability progression in multiple sclerosis — but the benefit is strongest in patients with a specific genetic profile. A new Swedish population study found that elevated EBNA1 antibody levels were tied to a lower risk of confirmed disability worsening, particularly in MS patients carrying both the HLA-A02:01 and HLA-DRB115:01 gene variants.
A new study published in the Journal of Neurology, Neurosurgery & Psychiatry adds a nuanced twist to the EBV-MS story: it's not just whether you have the virus antibodies, but how your immune genetics interact with them. Researchers from Karolinska Institutet analyzed data from two large Swedish MS cohorts and found that higher serum levels of Epstein-Barr virus nuclear antigen 1 (EBNA1) antibodies were associated with a reduced risk of confirmed disability worsening (CDW) over time.
The protective signal was strongest in patients carrying both HLA-DRB115:01 — the top genetic risk allele for MS — and HLA-A02:01, which is associated with reduced MS risk. In this subgroup, higher EBNA1 levels were linked to a 13% lower risk of CDW per standard deviation increase, and also reduced odds of reaching EDSS milestones of 3 and 4. The findings held up across multiple sensitivity analyses, including adjustments for treatment exposure and lifestyle factors.
By the Numbers:
Why it matters: This study suggests EBV immune responses don't just influence who gets MS — they may also shape how the disease progresses, depending on a patient's genetic makeup. It opens the door to more personalized, immunogenetic approaches to MS prognosis and biomarker research.
